Avalo Therapeutics reports Q2 EPS ($1.92), consensus ($1.48)

“The team has made tremendous progress on the execution of the Phase 2 LOTUS trial in hidradenitis suppurativa. We have enrolled over three-quarters of the planned patients and are on track to complete enrollment by year end with top-line results expected mid-2026,” said Dr. Garry Neil, Chief Executive Officer. “We are focused on executing the LOTUS trial and advancing toward Phase 3 readiness.”